European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - duloxetine - diabetic neuropathies - psychoanaleptics, - treatment of diabetic peripheral neuropathic pain in adults.

United Kingdom - English - myHealthbox

boehringer ingelheim international gmbh - tiotropium (as bromide monohydrate), olodaterol (as hydrochloride) - inhalation solution - 2.5 microgram/2.5 microgram per puff - drugs for obstructive airway diseases, adrenergics in combination with anticholinergics - it is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd)

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - tiotropium; olodaterol - inhalation solution - 2.5 µg/2.5 microgram(s) - anticholinergics; anticholinergics - drugs for obstructive airway diseases, adrenergics in combination with anticholinergics - it is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - pramipexole dihydrochloride monohydrate - restless legs syndrome; parkinson disease - anti-parkinson drugs - mirapexin is indicated for treatment of the signs and symptoms of idiopathic parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).mirapexin is indicated for symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in dosages up to 0.54 mg of base (0.75 mg of salt).

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - pramipexole dihydrochloride monohydrate - restless legs syndrome; parkinson disease - anti-parkinson drugs - sifrol is indicated for treatment of the signs and symptoms of idiopathic parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, though to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).sifrol is indicated for symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in dosages up to 0.54 mg of base (0.75 mg of salt).

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - meloxicam - tablet - 7.5 milligram(s) - oxicams; meloxicam

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - meloxicam - tablet - 15 milligram(s) - oxicams; meloxicam

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan - hypertension - cardiovascular system - treatment of essential hypertension in adults:add on therapyonduarp is indicated in adults whose blood pressure is not adequately controlled on amlodipine.replacement therapyadult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of onduarp containing the same component doses.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - immunosuppressants - please refer to section 4.1 of the summary of product characteristics in the product information document.,

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - clonidine hydrochloride - solution for injection - 150 microgram(s)/millilitre - imidazoline receptor agonists; clonidine